[go: up one dir, main page]

UA91044C2 - Жива послаблена ротавірусна вакцина для перорального застосування - Google Patents

Жива послаблена ротавірусна вакцина для перорального застосування

Info

Publication number
UA91044C2
UA91044C2 UAA200708765A UAA200708765A UA91044C2 UA 91044 C2 UA91044 C2 UA 91044C2 UA A200708765 A UAA200708765 A UA A200708765A UA A200708765 A UAA200708765 A UA A200708765A UA 91044 C2 UA91044 C2 UA 91044C2
Authority
UA
Ukraine
Prior art keywords
oral administration
live attenuated
rotavirus vaccine
attenuated rotavirus
phosphate
Prior art date
Application number
UAA200708765A
Other languages
English (en)
Russian (ru)
Inventor
Вельде Вінсент Ванде
Original Assignee
Ґлаксосмітклайн Байолоджікалз С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34385675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA91044(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ґлаксосмітклайн Байолоджікалз С.А. filed Critical Ґлаксосмітклайн Байолоджікалз С.А.
Publication of UA91044C2 publication Critical patent/UA91044C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Винахід стосується рідких ротавірусних композицій для перорального призначення малюкам людини, що містять ротавірусний антиген, цукор та карбоксилат, який є похідним дикарбонової кислоти. Вказана композиція має рН між 5,0 та 8,0 та містить менше 1 мМ фосфату.
UAA200708765A 2005-02-17 2006-02-15 Жива послаблена ротавірусна вакцина для перорального застосування UA91044C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0503337.8A GB0503337D0 (en) 2005-02-17 2005-02-17 Compositions
PCT/EP2006/001442 WO2006087205A1 (en) 2005-02-17 2006-02-15 Live attenuated rotavirus vaccine for oral administration

Publications (1)

Publication Number Publication Date
UA91044C2 true UA91044C2 (uk) 2010-06-25

Family

ID=34385675

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200708765A UA91044C2 (uk) 2005-02-17 2006-02-15 Жива послаблена ротавірусна вакцина для перорального застосування

Country Status (32)

Country Link
US (2) US8192747B2 (uk)
EP (2) EP2322211A1 (uk)
JP (1) JP5118977B2 (uk)
KR (1) KR101319846B1 (uk)
CN (2) CN101300028B (uk)
AP (1) AP2692A (uk)
AR (1) AR053680A1 (uk)
AT (1) ATE516044T1 (uk)
AU (1) AU2006215761B2 (uk)
BR (1) BRPI0608877B8 (uk)
CA (1) CA2598290C (uk)
CY (1) CY1111916T1 (uk)
DK (1) DK1863526T3 (uk)
EA (1) EA012046B1 (uk)
ES (1) ES2369246T3 (uk)
GB (1) GB0503337D0 (uk)
HR (1) HRP20110668T1 (uk)
IL (1) IL184802A0 (uk)
MA (1) MA29321B1 (uk)
MX (1) MX2007010075A (uk)
MY (1) MY145790A (uk)
NO (1) NO341789B1 (uk)
NZ (1) NZ560314A (uk)
PE (1) PE20061094A1 (uk)
PL (1) PL1863526T3 (uk)
PT (1) PT1863526E (uk)
SI (1) SI1863526T1 (uk)
TW (1) TWI358303B (uk)
UA (1) UA91044C2 (uk)
UY (1) UY29377A1 (uk)
WO (1) WO2006087205A1 (uk)
ZA (1) ZA200706668B (uk)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0711608B8 (pt) * 2006-05-12 2021-05-25 Bharat Biotech Int Ltd composição liofilizada, uso de antígeno viral, método de tratamento ou prevenção de vírus associado, método de adaptação de um vírus de uma linhagem celular adequada
EP2197283B1 (en) * 2007-09-25 2013-07-17 Aridis Pharmaceuticals Formulations for preservation of rota virus
EP2236617A1 (en) 2009-03-31 2010-10-06 Leukocare Ag Methods of terminal sterilization of biofunctional compositions
CN102695522B (zh) 2009-05-12 2016-10-19 美国政府(由卫生和人类服务部、疾病控制和预防中心的部长所代表) 新的人轮状病毒株和疫苗
CN101972475B (zh) * 2010-04-12 2014-04-09 李建平 一种细菌多糖-蛋白结合疫苗及其制备方法
CN101863966B (zh) * 2010-05-21 2012-10-03 中国人民解放军第三军医大学 抗轮状病毒药物作用靶标及其构建方法和应用方法
JP6000253B2 (ja) 2010-09-24 2016-09-28 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 胃腸機能を改善するための材料および方法
EP2471554A1 (en) * 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
WO2012103464A2 (en) * 2011-01-28 2012-08-02 Brian Pulliam Oral thin film vaccine preparation
WO2012149404A2 (en) * 2011-04-28 2012-11-01 International Medica Foundation Liquid vaccine preparations
CN102349932B (zh) * 2011-10-12 2012-12-26 刘壮华 一种治疗息肉的药物制剂
WO2013105105A2 (en) * 2012-01-13 2013-07-18 Serum Institute Of India Ltd. Novel viral vaccine compositions and methods for preparing such vaccines
MX368543B (es) * 2012-02-08 2019-10-07 Univ Florida Composiciones para tratar diarrea inducida por rotavirus.
BR112014020930A2 (pt) * 2012-03-05 2017-06-27 De Staat Der Nederlanden Vert Door De Mini Van Vws Miniie Van Volksgezondheid Welzijn En Sport método para produzir uma formulação seca de um agente biofármaco, e, formulação de um agente biofármaco
JP6126684B2 (ja) 2012-04-23 2017-05-10 バハラ バイオテック インターナショナル リミテッド 新規なロタウイルスワクチン組成物及び同組成物を調製する方法
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
WO2014164736A1 (en) 2013-03-11 2014-10-09 University Of Florida Research Foundation, Incorporated Materials and methods for improving lung function and for prevention and/or treatment of radiation-induced lung complications
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
CN103316336B (zh) * 2013-05-31 2015-01-28 北京科兴中维生物技术有限公司 一种适于口服的轮状病毒疫苗
CN103316335B (zh) * 2013-05-31 2014-11-12 北京科兴生物制品有限公司 一种适于口服的脊髓灰质炎病毒疫苗
MX380569B (es) * 2013-07-19 2025-03-12 Hexal Ag Métodos y formulaciones que permiten la modulación de respuestas inmunitarias relacionadas con la administración de un fármaco biofarmacéutico.
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
WO2015050177A1 (ja) * 2013-10-03 2015-04-09 日東電工株式会社 インフルエンザワクチン乾燥製剤、及び、インフルエンザワクチン乾燥製剤の製造方法
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
CN113730564A (zh) * 2014-12-08 2021-12-03 武汉生物制品研究所有限责任公司 口服六价重配轮状病毒活疫苗
US10548970B2 (en) 2015-10-05 2020-02-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human rotavirus G9P[6] strain and use as a vaccine
WO2017106115A1 (en) 2015-12-18 2017-06-22 Merck Sharp & Dohme Corp. Thermally stable rotavirus vaccine formulations and methods of use thereof
MA44557B1 (fr) 2016-06-16 2021-11-30 Bharat Biotech Int Ltd Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer
GB201614799D0 (en) * 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
BR112020021134A2 (pt) * 2018-04-16 2021-03-23 Merck Patent Gmbh aditivos para formulações de proteínas para aprimorar estabilidade térmica
CN110946871A (zh) * 2019-12-12 2020-04-03 浙江华康药业股份有限公司 槐糖在制备预防和治疗肥胖产品中的应用及对应产品
CN115531364B (zh) * 2021-06-30 2024-02-23 中国科学技术大学 预防或治疗轮状病毒感染的微生物代谢物制剂及其用途
CN113994925B (zh) * 2021-12-30 2022-04-26 北京赛尔富森生物科技有限公司 一种轮状病毒攻毒动物模型及其建立方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2505657A1 (fr) 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
JP2849632B2 (ja) 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE69130068T2 (de) * 1990-11-16 1999-01-07 Children's Hospital Medical Center, Cincinnati, Ohio Humane rotativen, impfstoffe und methoden
NZ240818A (en) * 1990-12-14 1993-08-26 Mcneil Ppc Inc Liquid sucralose concentrate compositions containing preservative, buffer and liquid
HUT67006A (en) * 1991-08-05 1995-01-30 Sterling Winthrop Inc Buffered composition containing mammalian superoxide-dismutase/polyethylene glycol coniugate
CA2085827C (en) 1991-12-23 2003-10-14 Lucas A. T. Hilgers Adjuvant composition containing synthetic hydrophobic lipopolysaccharide
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
EP0761231B1 (en) 1992-06-25 2000-01-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
ES2162139T5 (es) 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
CN1055093C (zh) 1993-11-17 2000-08-02 实验室奥姆公司 葡糖胺二糖类、其制备方法和用途、以及含有这些二糖的药物组合物
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6019982A (en) 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
US5932223A (en) * 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
EP0939648B1 (en) 1996-09-26 2007-11-07 Merck & Co., Inc. Rotavirus vaccine formulations
US6616931B1 (en) * 1996-09-26 2003-09-09 Merck & Co., Inc. Rotavirus vaccine formulations
US6403098B1 (en) * 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
CA2284586C (en) 1997-04-01 2011-02-08 Ribi Immunochem Research, Inc. Aqueous immunologic adjuvant compositions of monophosphoryl lipid a
EP0988053A1 (en) 1997-06-11 2000-03-29 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
DE69838992T2 (de) 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Öl-in-Wasser Emulsionen mit Saponinen
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9725084D0 (en) * 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
US6919076B1 (en) * 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
SK18602000A3 (sk) 1998-06-08 2001-07-10 Sca Emballage France Obal umožňujúci rýchle vyrovnanie
CZ302062B6 (cs) 1998-06-30 2010-09-22 Om Pharma Derivát acyldipeptidu, zpusob jeho prípravy, meziprodukty pro jeho prípravu a farmaceutický prostredek, který ho obsahuje
HK1046860B (en) * 1999-08-17 2006-10-06 Smithkline Beecham Biologicals S.A. Method of separating rotavirus variants and live attenuated rotavirus vaccine
AU1581400A (en) 1999-12-22 2001-07-03 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
AU784344B2 (en) * 2000-01-28 2006-03-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and method for preventing reactogenicity associated with administration of immunogenic live rotavirus compositions

Also Published As

Publication number Publication date
BRPI0608877B1 (pt) 2021-02-09
EA012046B1 (ru) 2009-08-28
AR053680A1 (es) 2007-05-16
CY1111916T1 (el) 2015-11-04
KR20070103506A (ko) 2007-10-23
EP2322211A1 (en) 2011-05-18
NO341789B1 (no) 2018-01-22
NO20073868L (no) 2007-11-15
US8192747B2 (en) 2012-06-05
PT1863526E (pt) 2011-10-11
BRPI0608877A2 (pt) 2012-07-31
US8821891B2 (en) 2014-09-02
UY29377A1 (es) 2006-10-02
ZA200706668B (en) 2009-07-29
MY145790A (en) 2012-04-30
TWI358303B (en) 2012-02-21
AP2007004087A0 (en) 2007-08-31
SI1863526T1 (sl) 2011-11-30
PL1863526T3 (pl) 2011-12-30
ATE516044T1 (de) 2011-07-15
US20080166372A1 (en) 2008-07-10
ES2369246T3 (es) 2011-11-28
NZ560314A (en) 2011-02-25
TW200640486A (en) 2006-12-01
CN103357005A (zh) 2013-10-23
CN101300028B (zh) 2014-06-04
CN101300028A (zh) 2008-11-05
AU2006215761A1 (en) 2006-08-24
IL184802A0 (en) 2007-12-03
US20120237547A1 (en) 2012-09-20
HRP20110668T1 (hr) 2011-10-31
MA29321B1 (fr) 2008-03-03
KR101319846B1 (ko) 2013-10-22
EA200701519A1 (ru) 2008-02-28
DK1863526T3 (da) 2011-10-24
GB0503337D0 (en) 2005-03-23
JP5118977B2 (ja) 2013-01-16
EP1863526B1 (en) 2011-07-13
AU2006215761B2 (en) 2011-03-17
CA2598290C (en) 2015-08-11
PE20061094A1 (es) 2006-11-30
AP2692A (en) 2013-07-16
JP2008530165A (ja) 2008-08-07
WO2006087205A1 (en) 2006-08-24
BRPI0608877B8 (pt) 2021-05-25
CA2598290A1 (en) 2006-08-24
EP1863526A1 (en) 2007-12-12
MX2007010075A (es) 2008-01-16

Similar Documents

Publication Publication Date Title
UA91044C2 (uk) Жива послаблена ротавірусна вакцина для перорального застосування
CA3094580C (en) Oral formulations of cytidine analogs and methods of use thereof
EP4582105A3 (en) Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
MEP18208A (en) Immune response modifier foam formulations
MX2009001412A (es) Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
MX2011011772A (es) Formulaicones estables de anticuerpos humanos anti-tnf-alfa con alta concentracion de proteina.
WO2007054279A3 (en) Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions
BRPI0607549A2 (pt) sistemas de distribuição farmacêutica para fármacos hidrófobos e composições compreendendo os mesmos
MY143795A (en) Tetrahydropyridoindole derivatives
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
GB2451216A (en) A composition useful as a vaccine
IL189104A (en) Pharmaceutical preparation containing lasalazide or sodium balasalazide for use in the treatment of gastrointestinal disorders.
EP1206189A4 (en) ROTAVIRUS VACCINE FORMULATIONS
WO2008054535A3 (en) Novel influenza m2 vaccines
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
AU2003236156A1 (en) Pharmaceutical compositions used for immune disease treatment and improvement
SI1433478T1 (sl) Farmacevtske formulacije za tiroidne hormone in postopki za njihovo pripravo
HUP0102159A2 (hu) Készítmény savtúltengés kezelésére
WO2007107328A3 (en) Subcutaneous implants containing a degradation-resistant polylactide polymer and a lh-rh analogue
WO2007059931A8 (en) New adjuvants on the basis of bisacyloxypropylcysteine conjugates and derivatives and their uses in pharmaceutical compositions
IL179177A (en) A pharmaceutical product including acyclovir and delivery compound, dosage unit, use of acyclovir in the preparation of the pharmaceutical product, use of the pharmaceutical product in the preparation of a drug and a method for the preparation of the pharmaceutical product
WO2007098716A8 (es) Compuestos analogos a los secretagogos peptidicos de la hormona de crecimiento y preparaciones que los contienen
ATE457721T1 (de) An titandioxidnanopartikeln absorbierte pharmazeutische wirkstoffe enthaltende pharmazeutische formulierungen
TW200611697A (en) Generally linear effervescent oral fentanyl dosage form and methods of administering
MD3121G2 (ro) Metodă de profilaxie a hepatitei virale B